Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
November 22, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 16:25 ET
|
Werewolf Therapeutics, Inc.
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – ...
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 03, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard...
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 31, 2023 09:00 ET
|
Werewolf Therapeutics, Inc.
Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in...
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023 09:00 ET
|
Werewolf Therapeutics, Inc.
Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim first-in-human clinical data from...
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
September 11, 2023 16:05 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
September 05, 2023 16:05 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:10 ET
|
Werewolf Therapeutics, Inc.
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm...
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
- Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023...